Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Peginterferon Alfa-2a and Ribavirin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Peginterferon Alfa-2a and Ribavirin | DRUG | Patients will be treated with alfa-2a and ribavirin as follows: Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly. |
| Ribavirin | DRUG | Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight \> 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg. |
Inclusion Criteria: * Diagnosis of thalassemia * Serum positive for hepatitis C virus RNA by polymerase chain reaction (PCR) test (using the Roche COBAS Amplicor hepatitis C virus test) * Hepatitis B surface antigen (HBsAg) negative and HIV negative within the 12 months prior to study entry * Liver...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Peginterferon Alfa-2a and Ribavirin is a combination therapy used for the treatment of Hepatitis C. It is being studied in patients who also have thalassemia, a blood disorder. The drug is currently in Phase 2 clinical development and is considered investigational.
Peginterferon Alfa-2a and Ribavirin is being developed by Elevance Health, Inc., a company traded on the stock exchange under the ticker symbol ELV. The company is conducting clinical research to evaluate the safety and efficacy of this combination therapy for Hepatitis C.
Peginterferon Alfa-2a and Ribavirin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to assess its safety in patients with Hepatitis C and thalassemia.
Peginterferon Alfa-2a and Ribavirin has been studied in one completed clinical trial, identified as NCT00502788. This Phase 2 study, titled 'Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)', enrolled 21 participants across the United States, Canada, and the United Kingdom.
Peginterferon Alfa-2a and Ribavirin is not FDA approved. It is an investigational combination therapy currently in Phase 2 clinical development for Hepatitis C. The drug has not completed the clinical trial process required for regulatory approval and remains under investigation.